An eight-week shatavari study reported sexual-function gains versus placebo. Read the findings, study limits and comparison with a different extract.
On October 23, 2026, Nutritional Outlook reported on an eight-week placebo-controlled study of SRI-81 shatavari tested alone and with KSM-66 ashwagandha in women. According to the report, the study was published in the International Journal of Women’s Health and found improvements in selected sexual-function outcomes.
The central question is not simply whether scores improved. It is which comparison improved and what that result means for women trying to understand changes in sexual wellbeing.
According to Nutritional Outlook, the study had three groups: SRI-81 shatavari alone, SRI-81 combined with KSM-66 ashwagandha and placebo. The researchers followed outcomes over eight weeks. This was a study testing particular formulations rather than a survey of existing supplement habits.
The reported outcomes included the total Female Sexual Function Index score, usually shortened to FSFI. The report also described results for arousal, lubrication and orgasm. These domain scores concern particular aspects of sexual function rather than treating every sexual experience as the same outcome.
The design allowed different questions to be examined. Comparing the combination with placebo asks whether the combination produced a different result from the control group. Comparing the combination with SRI-81 alone asks whether adding ashwagandha produced a higher overall score.
Those questions are related but not interchangeable. A positive finding against placebo does not automatically establish an advantage over another active study group. Keeping the comparisons separate is essential to reading this report accurately.
The report says the combination group improved its total FSFI score compared with placebo, with a reported p-value of p=0.005. It also describes improvements in the arousal, lubrication and orgasm domains.
These findings support a measured statement: the tested combination showed differences from placebo on the reported outcomes during the study. They do not support the broader claim that every shatavari product improves every aspect of sexual function.
The comparison with shatavari alone is especially important. The combination group’s total FSFI score was not significantly different from the SRI-81-only group, with p=0.862. The report therefore does not show that adding ashwagandha produced a superior overall sexual-function score.
That is not the same as proving the formulations are equivalent. It means this study did not establish the claimed advantage on that measure. A headline about the combination should preserve that distinction rather than presenting the added ingredient as the reason for the result.
The combination group also reported more intercourse than the placebo group, with p=0.001. That is a separate reported outcome, not a standard readers need to meet. More frequent intercourse should not be treated as a universal definition of better sexual wellbeing.
The p-values also need careful reading. They describe statistical comparisons rather than the size of an improvement or the percentage of participants who benefited. Statistical significance alone does not explain how noticeable a change was in everyday life.
As summarized by Nutritional Outlook, the paper’s authors identify a small sample and short follow-up as important limitations. They also note that the outcomes were self-reported. Their description of the work as exploratory is central to interpreting the findings.
Self-reported experiences matter in sexual wellbeing. Still, reported changes in experience are different from demonstrating a biological mechanism. The findings should be read as the outcomes the study measured rather than as proof of how the formulations might work.
The report says menstrual status was not controlled. This leaves uncertainty about how that factor may have influenced the comparisons. No correction was applied for multiple secondary comparisons, which makes the individual secondary findings more tentative.
That matters when several domain improvements appear together in a summary. The list should not be read as equally strong confirmation of a separate benefit in every area. The authors’ caution belongs alongside those results rather than being separated from them.
There are also gaps in the available study description. Nutritional Outlook does not provide the exact sample size, participant characteristics or supplement doses for this trial. Those details should not be borrowed from another shatavari study to make this one appear more fully described.
On safety, the report says mild adverse events occurred in all three groups and resolved without intervention. That observation does not establish long-term safety. The authors call for larger and longer trials, and the current findings do not establish lasting effectiveness either.
The commercial connection also deserves clear disclosure. The report says Ixoreal supplied the extracts but had no role in study design, analysis or interpretation. It also says the authors reported no conflicts of interest.
Those disclosures identify the supplier’s stated involvement. They should neither be omitted nor treated as proof that every possible source of bias was absent. The appropriate assessment remains focused on the study’s methods and results.
A separate Nutritional Outlook report describes another placebo-controlled shatavari study. That trial involved 70 reproductive-age women with low-libido characteristics and tested a different standardized shatavari root extract over 56 days.
For that separate study, the report gives a 3.3-point between-group difference in total FSFI at Day 56. The reported 95% CI was 1.6 to 5.0. It also notes limitations associated with the small, single-site, eight-week design.
The point difference gives information about the size of the score difference in that particular trial. It belongs to that extract and study population. It must not be attached to the SRI-81 study or presented as the benefit a reader should expect from the combination discussed here.
Together, the reports provide examples of short-term placebo-controlled research on shatavari and women’s sexual function. They offer a more useful context than treating the latest report as a final answer on its own.
They are not interchangeable versions of the same experiment. The extracts and study populations differ, so the findings do not establish that shatavari products generally have the same effects. Nor does the separate trial supply the missing participant details for the SRI-81 study.
The evidence therefore concerns specific products tested under specific conditions. That is a narrower conclusion than a general claim about shatavari, but it is also a more accurate starting point for future research.
For readers in midlife, the practical value is not a ready-made supplement plan. It is a clearer way to separate the outcome a study measured from the concern someone is actually experiencing.
A report about lubrication should not automatically be read as an answer about desire. Likewise, a change in an overall questionnaire score does not explain why a particular person’s sexual experience has changed. Beginning with the specific symptom rather than a broad label keeps that distinction visible.
The reported results do not establish that the formulation addresses the causes of changes associated with menopause or medication. They also do not resolve questions involving health conditions, relationship context or other life circumstances. These are matters for individual assessment rather than conclusions supplied by a group average.
For a discussion with a qualified clinician, useful questions arising from this research include:
These questions keep the focus on understanding the concern before assuming an explanation. Sexential’s coverage of desire in the context of everyday life offers a related educational perspective without turning one study into an individual diagnosis.
Relationship questions also deserve their own space. A supplement result should not become a judgement about a partner’s interest or commitment. Discussion of different levels of desire without blame addresses a different question from whether a study group’s score changed.
For anyone considering a supplement because of a sexual concern, personal decisions belong with qualified care rather than a research headline. The useful outcome is a better-informed conversation about the experience that matters to that person.
A change in sexual experience can deserve attention without becoming a verdict on health, age or a relationship.
Deciding whether a supplement headline answers a question about changing desire is where Sexential’s educational role begins. For adults aged 35 to 65 facing confusion about libido or arousal, its evidence-aware writing connects biology with everyday context to make those questions clearer while keeping education separate from personal treatment decisions.
Follow Sexential for thoughtful guidance on desire, sexual function, hormones, confidence, relationships and intimacy. Explore new articles and evidence-aware resources for sexual wellbeing across adulthood.
Changing desire, sleep and concentration deserve a care conversation. Read a clinician's argument alongside menopause guidance and its limits.
A Medscape review of women’s responses after orgasm puts a 117-participant study in context, without making continued activity an expectation.
A large Epic Research review raises questions about repeat testing before testosterone prescriptions. Learn how the findings fit diagnostic guidance.
Explore practical resources on desire, function, hormones, confidence, intimacy and sexual wellbeing.
Read the Blog
